Absence of prognostic significance of bcl-2 immunopositivity in non- small cell lung cancer: Analysis of 427 cases

Human Pathology

Volumn 28, Issue 9, 1997, Pages 1079-1082

  Anton, Rose C ^a,b   Brown, Richard W ^a   Younes, Mamoun ^a   Gondo, Margaret M ^a   Stephenson, Mark A ^a   Cagle, Philip T ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bcl 2; Immunohistochemistry; Lung; Non small cell carcinoma; Prognostic factors

Indexed keywords

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PROGNOSIS;

EID: 0030928745     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90062-9     Document Type: Article

References (17)

1. Minna JD, Pass H, Galstein E, et al: Cancer of the lung, in Devita VT, Hellman S, Rosemberg SA (eds): Cancer, Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1989, pp 591-705
2. Parker SH, Tong T, Bolden S, et al: Cancer Statistics, 1996. CA Cancer J Clin 46:5-27, 1996
3. Hockenbery D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
4. Pezzella F, Tse AGD, Cordell JL, et al: Expression of the bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am J Pathol 137:225-232, 1990
5. Pezzella F, Gatter K: What is the value of bcl-2 protein detection for histopathologists? Histopathology 26:89-93, 1995
6. Zutter M, Hockenbery D, Silverman GA, et al: Immunolocalization of the bcl-2 protein within hematopoietic neoplasms. Blood 78:1062-1068, 1991
7. Bhargava V, Kell DL, van de Rijn M, et al: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540, 1994
8. Doglioni C, Dei Tos AP, Laurino L, et al: The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 424:47-51, 1994
9. Castle VP, Heidelberger KP, Bromberg J, et al: Expression of the apoptosis-suppressing protein bcl-2 in neuroblastoma is associated with unfavorable histology and n-myc amplification. Am J Pathol 143:1543-1550, 1993
10. Lu Q, Elia G, Lucas S, et al: Bcl-2 proto-oncogene expression in Epstein-Barr virus associated nasopharyngeal carcinoma. Int J Cancer 53:29-35, 1993
11. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992
12. Ayhan A, Yasui W, Yokozaki H, et al: Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J Cancer Res 85:584-591, 1994
13. Ritter JH, Dresler CM, Wick MR: Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. HUM PATHOL 26:1227-1232, 1995
14. Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694, 1993
15. Fontanini G, Vignati S, Bigini D, et al: Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71:1003-1007, 1995
16. Fleming MV, Guinee DG, Chu WS, et al: Correlates of bcl-2 immunohistochemical staining in a surgical series of lung cancer patients. Mod Pathol 8:148A, 1995
17. Xu HJ, Cagle PT, Hu SX, et al: Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis. Clin Cancer Res 2:1169, 1996